Literature DB >> 15476231

Intramolecular T cell spreading in unprimed MRL/lpr mice: importance of the U1-70k protein sequence 131-151.

Fanny Monneaux1, Véronique Parietti, Jean-Paul Briand, Sylviane Muller.   

Abstract

OBJECTIVE: To analyze spontaneous T cell spreading against determinants of the U1-70K protein in young autoimmune MRL/lpr lupus mice, in comparison with the T cell spreading occurring in normal BALB/c mice immunized with peptide 131-151 of this protein.
METHODS: Peripheral blood lymphocytes (PBLs) from both unprimed MRL/lpr mice and immunized BALB/c mice were tested for their ability to proliferate ex vivo in response to 18 overlapping peptides of the U1-70K spliceosomal protein, using assays for lymphocyte proliferation and secretion of interleukin-2.
RESULTS: The proliferative response to peptides of the U1-70K protein evolved rapidly in MRL/lpr mice tested at different ages. At least 5 peptides were recognized by PBLs from 8-week-old autoimmune mice, whereas a different peptide was recognized by PBLs from MRL/lpr mice at 12 weeks of age. At 15 weeks, the proliferative response was weak or negative when assessed with any of the test peptides. At least 2 major peptides recognized by MRL/lpr PBLs were also recognized by PBLs generated in the BALB/c mice primed with peptide 131-151. We further demonstrated that, in preautoimmune MRL/lpr mice, repeated administration of phosphorylated peptide 131-151 (called P140), which was shown previously to be protective, transiently abolished T cell intramolecular spreading to other regions of the 70K protein.
CONCLUSION: This is the first study to demonstrate that intramolecular T cell spreading effectively occurs in MRL/lpr mice with lupus, and that region 131-151 is important in the cascade of events observed in the murine lupus response. This sequence might originate a mechanism of tolerance spreading that leads to the beneficial effect observed in MRL/lpr mice after treatment with the phosphorylated peptide 131-151. Copyright 2004 American College of Rheumatology

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15476231     DOI: 10.1002/art.20510

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  7 in total

Review 1.  The U1-snRNP complex: structural properties relating to autoimmune pathogenesis in rheumatic diseases.

Authors:  Nicole H Kattah; Michael G Kattah; Paul J Utz
Journal:  Immunol Rev       Date:  2010-01       Impact factor: 12.988

2.  CD4+ T cells target epitopes residing within the RNA-binding domain of the U1-70-kDa small nuclear ribonucleoprotein autoantigen and have restricted TCR diversity in an HLA-DR4-transgenic murine model of mixed connective tissue disease.

Authors:  Eric L Greidinger; Yun Juan Zang; Kimberly Jaimes; Laisel Martinez; Mehdi Nassiri; Robert W Hoffman
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

3.  HSC70 blockade by the therapeutic peptide P140 affects autophagic processes and endogenous MHCII presentation in murine lupus.

Authors:  Nicolas Page; Frédéric Gros; Nicolas Schall; Marion Décossas; Dominique Bagnard; Jean-Paul Briand; Sylviane Muller
Journal:  Ann Rheum Dis       Date:  2010-12-20       Impact factor: 19.103

4.  Importance of spliceosomal RNP1 motif for intermolecular T-B cell spreading and tolerance restoration in lupus.

Authors:  Fanny Monneaux; Véronique Parietti; Jean-Paul Briand; Sylviane Muller
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

5.  Modulation of deregulated chaperone-mediated autophagy by a phosphopeptide.

Authors:  Christophe Macri; Fengjuan Wang; Inmaculada Tasset; Nicolas Schall; Nicolas Page; Jean-Paul Briand; Ana Maria Cuervo; Sylviane Muller
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

6.  The spliceosomal phosphopeptide P140 controls the lupus disease by interacting with the HSC70 protein and via a mechanism mediated by gammadelta T cells.

Authors:  Nicolas Page; Nicolas Schall; Jean-Marc Strub; Marc Quinternet; Olivier Chaloin; Marion Décossas; Manh Thong Cung; Alain Van Dorsselaer; Jean-Paul Briand; Sylviane Muller
Journal:  PLoS One       Date:  2009-04-23       Impact factor: 3.240

7.  Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial.

Authors:  Robert Zimmer; Hugo R Scherbarth; Oscar Luis Rillo; Juan Jesus Gomez-Reino; Sylviane Muller
Journal:  Ann Rheum Dis       Date:  2012-11-21       Impact factor: 19.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.